Suscripción a Biblioteca: Guest
Portal Digitalde Biblioteca Digital eLibros Revistas Referencias y Libros de Ponencias Colecciones
Critical Reviews™ in Immunology
Factor de Impacto: 1.404 Factor de Impacto de 5 años: 3.347 SJR: 0.706 SNIP: 0.55 CiteScore™: 2.19

ISSN Imprimir: 1040-8401
ISSN En Línea: 2162-6472

Volumen 40, 2020 Volumen 39, 2019 Volumen 38, 2018 Volumen 37, 2017 Volumen 36, 2016 Volumen 35, 2015 Volumen 34, 2014 Volumen 33, 2013 Volumen 32, 2012 Volumen 31, 2011 Volumen 30, 2010 Volumen 29, 2009 Volumen 28, 2008 Volumen 27, 2007 Volumen 26, 2006 Volumen 25, 2005 Volumen 24, 2004 Volumen 23, 2003 Volumen 22, 2002 Volumen 21, 2001 Volumen 20, 2000 Volumen 19, 1999 Volumen 18, 1998 Volumen 17, 1997 Volumen 16, 1996 Volumen 15, 1995 Volumen 14, 1994

Critical Reviews™ in Immunology

DOI: 10.1615/CritRevImmunol.v15.i1.30
pages 77-105

lnterleukin-1 Receptor Antagonist

Andrew C. Lennard
Yamanouchi Research Institute U.K., Littlemore Hospital, Oxford OX4 4XN, U.K.


The interleukin-1 receptor antagonist (IL-lra) is unusual in that it is the only known naturally occurring, cytokine receptor antagonist with no apparent agonist function. Over the last 5 years, since the cloning of the IL-lra cDNA sequence, there has been intensive research on the genetics, regulation, and potential therapeutic value of this protein. The later discovery of a second form of IL-lra in 1991 has complicated the picture. Whereas the originally described IL-lra is predominantly glycosylated and secreted (sIL-lra), the alternative isoform is unglycosylated and intracellular (icIL-lra). Although the biological roles of the two forms are still open to question, IL-lra is likely to be of great importance in the pathogenesis of both acute and chronic inflammatory diseases. A large body of evidence for this conclusion has come from animal models of inflammatory disease that respond well to administration of exogenous IL-lra. A role for recombinant IL-lra in the management of human disease is still under investigation. The two forms of IL-lra are encoded by a single gene by alternative usage of two first exons. Expression of sIL-lra and icIl-lra is regulated by two promoters. In this review I explore the genetics of the gene encoding IL-lra (IL-1RN) and the mechanisms of IL-lra gene activation to produce sIL-lra and icIL-lra. Also, possible biological roles for these immunomodulators in health and disease are discussed.

Articles with similar content:

lnterleukin-1 Receptor Antagonist
Critical Reviews™ in Immunology, Vol.37, 2017, issue 2-6
Andrew C. Lennard
Neuronal NOS: Gene Structure, mRNA Diversity, and Functional Relevance
Critical Reviews™ in Neurobiology, Vol.13, 1999, issue 1
Derek C. Newton, Philip A. Marsden, Yang Wang
Phosphatidylenthanolamine Binding Protein aka Raf Kinase Inhibitor Protein: A Brief History of Its Discovery and the Remarkable Diversity of Biological Functions
Forum on Immunopathological Diseases and Therapeutics, Vol.2, 2011, issue 1
John M. Sedivy
Akirin2-Mediated Transcriptional Control by Recruiting SWI/SNF Complex in B Cells
Critical Reviews™ in Immunology, Vol.36, 2016, issue 5
Osamu Takeuchi, Sarang Tartey
Expression of Members of the Dystrophin, Dystrobrevin, and Dystrotelin Superfamily
Critical Reviews™ in Eukaryotic Gene Expression, Vol.19, 2009, issue 2
Roland G. Roberts, Sabrina V. Bohm